Puma Biotechnology Inc (PBYI): Price and Financial Metrics

Puma Biotechnology Inc (PBYI): $3.74

0.21 (-5.32%)

POWR Rating

Component Grades








Add PBYI to Watchlist
Sign Up

Industry: Biotech




#28 of 339

in industry

PBYI Price/Volume Stats

Current price $3.74 52-week high $7.73
Prev. close $3.95 52-week low $2.13
Day low $3.74 Volume 206,460
Day high $4.07 Avg. volume 526,102
50-day MA $3.72 Dividend yield N/A
200-day MA $4.28 Market Cap 180.41M

PBYI Stock Price Chart Interactive Chart >

Puma Biotechnology Inc (PBYI) Company Bio

Puma Biotechnology is a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. The company was founded in 2010 and is based in Los Angeles, California.

PBYI Latest News Stream

Event/Time News Detail
Loading, please wait...

PBYI Latest Social Stream

Loading social stream, please wait...

View Full PBYI Social Stream

Latest PBYI News From Around the Web

Below are the latest news stories about PUMA BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate PBYI as an investment opportunity.

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.

Yahoo | December 28, 2023

Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody

The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.

Yahoo | December 28, 2023

Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.

Yahoo | December 26, 2023

Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis

Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.

Yahoo | December 26, 2023

Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program

Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.

Yahoo | December 22, 2023

Read More 'PBYI' Stories Here

PBYI Price Returns

1-mo 16.88%
3-mo -25.05%
6-mo -20.59%
1-year 12.99%
3-year -53.83%
5-year -63.33%
YTD -13.63%
2023 2.36%
2022 39.14%
2021 -70.37%
2020 17.26%
2019 -57.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!